Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome

Urology

Volumn 43, Issue 3, 1994, Pages 408-410

  Small, Eric J ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BLOOD LEVEL; CASE REPORT; CLINICAL TRIAL; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; ANILIDES; CASE REPORT; HUMAN; MALE; MIDDLE AGE; PROSTATE-SPECIFIC ANTIGEN; SUBSTANCE WITHDRAWAL SYNDROME; SUPPORT, NON-U.S. GOV'T;

EID: 0028256111     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/0090-4295(94)90092-2     Document Type: Article

References (6)

1. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome
2. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer
3. Orchiectomy and nilutimide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
4. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma
5. Clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
6. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.